Denmark To Adopt QALY For Cost-Effectiveness Assessments
Using the QALY is expected to help the Danish Medicines Council make its decisions on the cost effectiveness of drugs more transparent, but it will also extend the time the council takes to make a recommendation.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with seven new products including Roche's Polivy for treating diffuse large B-cell lymphoma. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
A number of new products have been submitted for review at the European Medicines Agency. While marketing authorization applications from ViiV Healthcare and BioMarin Pharmaceutical are being fast-tracked, a submission from Incyte is not.